Compare Abeona Therapeutics Inc (ABEO) vs Eni SpA (E) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Eni SpA — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Eni SpA trades at $48.39 (market cap $67.72B). The key difference: Eni SpA is far larger — about 181.4× Abeona Therapeutics Inc's market cap, and Eni SpA pays a 5.25% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | E | |
|---|---|---|
Market Cap | $373.32M | $67.72B |
Sector | Health | Energy |
52-Week High | $7.23 | $57.61 |
52-Week Low | $4.17 | $32.93 |
Enterprise Value | $228.22M | $86.63B |
Dividend Yield | — | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Eni (E) trades at $47.47, up 1.28% with a bearish technical signal despite recent earnings beats. The company shows stable cash flow generation with $13.33B operating cash flow in 2025 and maintains a reasonable valuation with P/E of 20.51 and P/S of 0.75. Recent strategic moves include lithium investments in Chile and fusion energy partnerships, signaling diversification beyond traditional energy operations.
While analyst consensus leans neutral (61.53% hold), Eni's transition strategy and global expansion present long-term opportunities. Key risks include declining revenue trends from $132.5B in 2022 to $82.15B in 2025 and competitive pressures in the energy sector. The stock offers value characteristics with dividend income potential amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →
